TECX
NASDAQTectonic Therapeutic Inc.
Price$28.64-1.52 (-5.06%)
01:45 PM07:45 PM
News · 26 weeks40-87%
2025-12-142026-06-07
Mix1390d
- SEC Filings5(38%)
- Insider4(31%)
- Analyst2(15%)
- Leadership1(8%)
- Other1(8%)
Latest news
25 items- ANALYSTTectonic Therapeutic upgraded by Raymond James with a new price targetRaymond James upgraded Tectonic Therapeutic from Outperform to Strong Buy and set a new price target of $81.00
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECSEC Form 10-Q filed by Tectonic Therapeutic Inc.10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business HighlightsTX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial in February 2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia ("HHT"), and as of April 2026, four cohorts have been dosed with topline results expected by the end of Q3 2026TX45 ALPINE Phase 2 clinical trial initiated in Pulmonary Hypertension in Heart Failure associated with Interstitial Lung Disease ("PH-ILD," Group 3 PH), with first site activated in February 2026 and screening initiated in March 2026, expanding TX45 into a second pulmonary hypertension indicationStrength
- INSIDERChief Medical Officer Ruddy Marcella K. sold $31,950 worth of shares (1,065 units at $30.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 67,682 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECSEC Form DEFA14A filed by Tectonic Therapeutic Inc.DEFA14A - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECSEC Form DEF 14A filed by Tectonic Therapeutic Inc.DEF 14A - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- PRTectonic Therapeutic Appoints Jessica Chutter to Board of DirectorsWATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with deep expertise advising biotechnology and pharmaceutical companies on strategic positioning, mergers and acquisitions, and capital markets execution. She is widely recognized as a pioneer in investment
- ANALYSTStifel initiated coverage on Tectonic Therapeutic with a new price targetStifel initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $75.00
- INSIDERSEC Form 4 filed by Ruddy Marcella K.4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 4 filed by Nader Francois4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nader Francois3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Medical Officer Ruddy Marcella K. sold $300,000 worth of shares (10,000 units at $30.00), decreasing direct ownership by 13% to 69,747 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Scientific Officer Mcnamara Peter sold $188,935 worth of shares (6,262 units at $30.17) and exercised 2,715 shares at a strike of $3.36, decreasing direct ownership by 6% to 55,285 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- SECSEC Form S-8 POS filed by Tectonic Therapeutic Inc.S-8 POS - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- INSIDERChief Executive Officer Reicin Alise was granted 76,500 shares, increasing direct ownership by 33% to 311,547 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Business Officer Schwabish Marc was granted 19,500 shares, increasing direct ownership by 76% to 45,314 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Scientific Officer Mcnamara Peter sold $77,627 worth of shares (3,299 units at $23.53) and was granted 23,000 shares, increasing direct ownership by 50% to 58,832 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Financial Officer Lochner Daniel was granted 26,500 shares, increasing direct ownership by 83% to 58,544 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERChief Medical Officer Ruddy Marcella K. was granted 26,500 shares, increasing direct ownership by 50% to 79,747 units (SEC Form 4)4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- INSIDERAmendment: Chief Executive Officer Reicin Alise bought $52,750 worth of shares (2,500 units at $21.10) (SEC Form 4)4/A - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
- PRTectonic Therapeutic to Participate in March Investor ConferencesWATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2026. TD Cowen 46th Annual Health Care Conference Date:March 4, 2026Time:11:10 AM ESTLocation:Boston, MAFormat:Fireside ChatPresenters:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link Leerink Global Healthcare Conference Date:March 11, 2026Time:1:40 PM ESTLocation:M
- SECSEC Form S-8 filed by Tectonic Therapeutic Inc.S-8 - Tectonic Therapeutic, Inc. (0001681087) (Filer)
- SECTectonic Therapeutic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
TECX FAQ
6 questionsWhere does TECX stock trade?
Tectonic Therapeutic Inc. (TECX) is listed on NASDAQ.What sector and industry is TECX in?
Tectonic Therapeutic Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Tectonic Therapeutic Inc. go public?
Tectonic Therapeutic Inc. (TECX) completed its IPO in 2018.What are analysts saying about TECX?
Tectonic Therapeutic Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy on 2026-05-26.What companies are similar to TECX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TECX side-by-side with any of them on Quantisnow.How can I track TECX on Quantisnow?
Quantisnow aggregates Tectonic Therapeutic Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TECX to receive live email and push alerts on every new disclosure.